Background Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum of disease states ranging from mild steatosis characterized by an abnormal retention of lipids within liver cells to steatohepatitis (NASH) showing fat accumulation, inflammation, ballooning and degradation of hepatocytes, and fibrosis. Ultimately, steatohepatitis can result in liver cirrhosis and hepatocellular carcinoma. Methodology and Results In this study we have analyzed three different mouse strains, A/J, C57BL/6J, and PWD/PhJ, that show different degrees of steatohepatitis when administered a 3,5-diethoxycarbonyl-1,4-dihydrocollidine(DDC) containing diet. RNA-Seq gene expression analysis, protein analysis and metabolic profiling were applied to identify diffe...
Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world and...
Although drug induced steatosis represents a mild type of hepatotoxicity it can progress into more s...
Background & AimsThe lack of a preclinical model of progressive non-alcoholic steatohepatitis (NASH)...
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum of disease states ranging...
<div><p>Background</p><p>Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum of disease s...
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum of disease states ranging...
BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum of disease states ranging ...
Background: Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum of disease states ranging...
Includes bibliographical references.Fatty liver disease is a collective phrase for a spectrum of dis...
BACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH), the potentially progressive form of nonal...
Background & AimsThe lack of a preclinical model of progressive non-alcoholic steatohepatitis (NASH)...
Introduction: non-alcoholic fatty liver disease is one of the most prevalent liver disorders in the ...
Background and aims Non-alcoholic steatohepatitis (NASH), the potentially progressive form of nonalc...
The pathophysiology of nonalcoholic fatty liver disease (NAFLD) is a complex process involving metab...
BACKGROUND & AIMS Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disor...
Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world and...
Although drug induced steatosis represents a mild type of hepatotoxicity it can progress into more s...
Background & AimsThe lack of a preclinical model of progressive non-alcoholic steatohepatitis (NASH)...
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum of disease states ranging...
<div><p>Background</p><p>Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum of disease s...
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum of disease states ranging...
BACKGROUND:Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum of disease states ranging ...
Background: Non-alcoholic fatty liver disease (NAFLD) has a broad spectrum of disease states ranging...
Includes bibliographical references.Fatty liver disease is a collective phrase for a spectrum of dis...
BACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH), the potentially progressive form of nonal...
Background & AimsThe lack of a preclinical model of progressive non-alcoholic steatohepatitis (NASH)...
Introduction: non-alcoholic fatty liver disease is one of the most prevalent liver disorders in the ...
Background and aims Non-alcoholic steatohepatitis (NASH), the potentially progressive form of nonalc...
The pathophysiology of nonalcoholic fatty liver disease (NAFLD) is a complex process involving metab...
BACKGROUND & AIMS Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disor...
Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world and...
Although drug induced steatosis represents a mild type of hepatotoxicity it can progress into more s...
Background & AimsThe lack of a preclinical model of progressive non-alcoholic steatohepatitis (NASH)...